The spectrum of pulmonary aspergillosis
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Notable progress has been made in the past years in the classification, diagnosis and treatment of pulmonary aspergillosis. New criteria were proposed by the Working Group of the International Society for Human and Animal Mycology (ISHAM) for the diagnosis of allergic bronchopulmonary aspergillosis (ABPA). The latest classification of chronic pulmonary aspergillosis (CPA) suggested by the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) has become widely accepted among clinicians. Subacute invasive pulmonary aspergillosis is now considered a type of CPA, yet it is still diagnosed and treated similarly to invasive pulmonary aspergillosis (IPA). Isavuconazole, an extended-spectrum triazole, has recently been approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of IPA. The most recent Infectious Diseases Society of America (IDSA) guidelines strongly recommend reducing mold exposure to patients at high risk for pulmonary aspergillosis. The excessive relapse rate following discontinuation of therapy remains a common reality to all forms of this semi-continuous spectrum of diseases. This highlights the need to continuously reassess patients and individualize therapy accordingly. Thus far, the duration of therapy and the frequency of follow-up have to be well characterized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management
Denning, D. W., Cadranel, J., Beigelman-Aubry, C., Ader, F., Chakrabarti, A., Blot, S., Ullmann, A. J., Dimopoulos, G., & Lange, C. (2016) · European Respiratory Journal · doi:10.1183/13993003.00583-2015 · Cited by 1,030
Maertens, J. A., Raad, I. I., Marr, K. A., Patterson, T. F., Kontoyiannis, D. P., Cornely, O. A., Bow, E. J., Rahav, G., Neofytos, D., Aoun, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01159-9 · Cited by 1,001
Agarwal, R., Chakrabarti, A., Shah, A., Gupta, D., Meis, J. F., Guleria, R., Moss, R., Denning, D. W., & ABPA complicating asthma ISHAM working group (2013) · Clinical & Experimental Allergy · doi:10.1111/cea.12141 · Cited by 896
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844
Denning, D. W., Pleuvry, A., & Cole, D. C. (2013) · Medical Mycology · doi:10.3109/13693786.2012.738312 · Cited by 495
Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma
Smith, N. L., & Denning, D. W. (2011) · European Respiratory Journal · doi:10.1183/09031936.00054810 · Cited by 449
Denning, D. W., Park, S., Lass-Florl, C., Fraczek, M. G., Kirwan, M., Gore, R., Smith, J., Bueid, A., Moore, C. B., Bowyer, P., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir179 · Cited by 313
Cited by
Bastos, R. W., Valero, C., Silva, L. P., Schoen, T., Drott, M., Brauer, V., Silva-Rocha, R., Lind, A., Steenwyk, J. L., Rokas, A., et al. (2020) · mSphere · doi:10.1128/msphere.00153-20 · Cited by 60
“aspergillosis with azoles and polyene drugs (11), both of which are known to interfere with the biosynthesis or physicochemical properties of fungal membrane sterols (10).”
Metadata
- Authors
- Kanj, A., Abdallah, N., & Soubani, A. O.
- Venue
- Respiratory Medicine
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 141
- Pages
- 121-131
- ISSN
- 0954-6111 (ISSN-L)
- OpenAlex
- W2810784262
- Cited by
- 174
- References
- 15
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The spectrum of pulmonary aspergillosis. https://app.cochat.ai/papers/10.1016/j.rmed.2018.06.029
- The paper
- Kanj, A., Abdallah, N., & Soubani, A. O. (2018). The spectrum of pulmonary aspergillosis. Respiratory Medicine. https://doi.org/10.1016/j.rmed.2018.06.029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.